Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone805-488-2800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$210,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/6/2019 (Estimated)
OptionableNot Optionable
Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions
What is Stellar Biotechnologies' stock symbol?
Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."
When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?
Stellar Biotechnologies's stock reverse split on the morning of Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.
How were Stellar Biotechnologies' earnings last quarter?
Stellar Biotechnologies Inc (NASDAQ:SBOT) issued its earnings results on Tuesday, February, 5th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.03. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $0.06 million. Stellar Biotechnologies had a negative net margin of 2,018.40% and a negative return on equity of 52.71%. View Stellar Biotechnologies' Earnings History.
When is Stellar Biotechnologies' next earnings date?
Has Stellar Biotechnologies been receiving favorable news coverage?
News stories about SBOT stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stellar Biotechnologies earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Stellar Biotechnologies' key competitors?
Some companies that are related to Stellar Biotechnologies include IMMURON LTD/S (IMRN), Onconova Therapeutics (ONTX), MOTIF BIO PLC/S (MTFB), Novelion Therapeutics (NVLN), Ceapro (CRPOF), Jaguar Health (JAGX), Fibrocell Science (FCSC), ESSA Pharma (EPIX), Dare Bioscience (DARE), BENITEC BIOPHAR/S (BNTC), Pain Therapeutics (PTIE), Sernova (SEOVF), Provectus Biopharmaceuticals (PVCT), Nuvo Pharmaceuticals (NRIFF) and Aptevo Therapeutics (APVO).
What other stocks do shareholders of Stellar Biotechnologies own?
Who are Stellar Biotechnologies' key executives?
Stellar Biotechnologies' management team includes the folowing people:
- Mr. Frank R. Oakes, Chairman, Pres & CEO (Age 69)
- Ms. Kathi Niffenegger CPA, CFO & Corp. Sec. (Age 62)
- Dr. Gregory T. Baxter, Exec. VP of Corp. Devel. (Age 60)
- Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
- Brando Lincicum, Exec. Director of Aquaculture and Facility Operations
How do I buy shares of Stellar Biotechnologies?
Shares of SBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stellar Biotechnologies' stock price today?
One share of SBOT stock can currently be purchased for approximately $1.16.
How big of a company is Stellar Biotechnologies?
Stellar Biotechnologies has a market capitalization of $6.18 million and generates $210,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.
What is Stellar Biotechnologies' official website?
How can I contact Stellar Biotechnologies?
Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]
MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe SBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
